Présentation de l'entreprise
Guardian Pharmacy Services, Inc. operates as a pharmacy service company that provides a comprehensive suite of technology-enabled services designed to assist residents within long-term health care facilities across the United States. The entity functions within the healthcare sector, specifically categorized under the medical care facilities industry, which implies a reliance on regulatory compliance and specialized clinical operations to manage drug dispensing and administration. The company's scale is substantial, evidenced by a market capitalization of $2.58B, annual revenue of $1.45B, and an organizational structure supporting 3600 employees. These valuation and revenue figures indicate that Guardian Pharmacy Services holds a significant position in its niche, commanding a market cap that reflects strong investor confidence in its ability to generate revenue through its clinical capabilities. The disparity between the company's large revenue base and its employee count suggests a capital-intensive business model typical of the medical care facilities industry, where operational costs are weighed against high-value service delivery to long-term care institutions.
Santé financière
Guardian Pharmacy Services, Inc. reported a trailing twelve-month revenue of $1.45B, generating a net income of $49.22M and an EBITDA of $102.62M. The substantial gap between the $1.45B revenue and the $49.22M net income reveals a cost structure where operating expenses consume approximately 96.6% of gross revenue, highlighting the operational intensity inherent in providing pharmaceutical services. The company generated free cash flow of $73.88M, which provides a critical buffer for financial flexibility, allowing management to fund operations, service debt, or pursue strategic opportunities without immediate reliance on external financing. Profitability metrics show a gross margin of 20.2%, an operating margin of 8.9%, and a profit margin of 3.4%; the relatively narrow profit margin indicates that after covering the cost of goods sold and operating expenses, the company retains a small portion of revenue as bottom-line profit. Regarding liquidity and leverage, the company holds $65.62M in cash against $44.72M in total debt, resulting in a debt-to-equity ratio of 20.52, which suggests a balance sheet that is moderately leveraged given the high equity base required to support this debt level. Short-term liquidity is supported by a current ratio of 1.38, indicating that the company possesses sufficient current assets to cover its current liabilities with a comfortable margin of safety. Return on equity stands at 26.6% and return on assets is 13.7%, metrics that reveal management is generating significant returns on shareholder capital while effectively utilizing the asset base to produce earnings.
Évaluation de la valorisation
The valuation metrics present a trailing P/E ratio of 51.32 and a forward P/E of 29.56, where the significant difference between these two figures implies that the market expects a substantial improvement in earnings trajectory over the coming fiscal periods to justify the current stock price. The price-to-book ratio is recorded at 12.32, indicating that the market values the company at more than twelve times its book value, which suggests a high premium assigned to the company's intangible assets, brand, and future growth prospects relative to its net asset value. Alternative valuation multiples include a price-to-sales ratio of 1.78 and an EV/EBITDA of 24.61; these metrics suggest that the company is priced at a premium relative to its sales and earnings power, reflecting expectations of continued market share gains or pricing power in the pharmacy services sector. Price action analysis shows a 52-week high of $41.36 and a 52-week low of $19.17, while the specific current trading price is not provided in the available facts, the wide range indicates significant volatility within the year. The beta value is listed as N/A, meaning that specific data regarding the stock's sensitivity to broader market movements is not available for this reporting period.
Growth & Income
Revenue growth for the trailing twelve-month period is recorded at 17.4%, while earnings growth is listed as N/A, preventing a direct comparison of the rates. The absence of reported earnings growth data limits the ability to determine whether earnings are expanding at a faster or slower pace than revenue, though the revenue expansion itself demonstrates strong top-line momentum. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all of its earnings into business growth, debt reduction, or other corporate strategies rather than distributing cash to shareholders. This non-dividend profile combined with the robust 17.4% revenue growth defines the overall growth and income profile as one focused entirely on capital appreciation and operational scaling rather than current income generation.